Summary
A total of 46 patients with previously untreated acute myeloid leukaemia were treated with an induction regimen consisting of 100 mg/m2 cytosine arabinoside given daily by 18-h i. v. infusion for 7 days, 50 mg/m2 daunorubicin given daily by i.v. bolus injection for 3 days and 75 mg/m2 etoposide given daily by 1-h i. v. infusion for 7 days. In all, 30 patients (67%) went into complete remission and were given further consolidation and maintenance chemotherapy. Of the 31 complete responders, 15 (48%) relapsed. The median disease-free survival of the 31 complete responders and the median overall survival of all 46 patients were 25 and 14 months, respectively. None of the clinical characteristics, which included sex, age, FAB morphology, extramedullary disease and initial WBC count, predicted the clinical response. Myelosuppression was the major toxicity and non-haematological side effects were acceptable. The regimen appeared to have acceptable toxicity, and its efficacy was comparable with that of standard regimens.
This is a preview of subscription content, log in via an institution to check access.
References
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Garlnick HR, Sultan C (1985) Proposed revised criteria for the classification of acute myeloid leukaemia — a report of the French-American-British Cooperative Group. Ann Intern Med 103: 626–629
Cavalli F, Sonntag R, Brunner KW (1975) Epipodophyllotoxin VP-16-213 in acute non-lymphoblastic leukaemia. Br Med J 4: 227
Gale RP, Foon K (1987) Therapy of acute myelogenous leukamia. Semin Hematol 24: 40–54
Gore M, Powles R, Lakhani A, Milan S, Maitland J, Goss G, Nandi A, Perren T, Forgeson G, Treleaven J, Porta F (1989) Treatment of relapsed and refractory acute leukaemia with high-dose cytosine arabinoside and etoposide. Cancer Chemother Pharmacol 23: 373–376
Mayer RJ (1987) Current chemotherapeutic approaches to the management of previously untreated adults with de novo acute myelogenous leukemia. Semin Oncol 14: 384–396
Odom LF, Gordon EM (1984) Acute monoblastic leukemia in infancy and early childhood: successful treatment with an epipodophyllotoxin. Blood 64: 875–882
Peterson BA, Levine EG (1987) Uncommon subtypes of acute non-lymphocytic leukemia: clinical features and management of FAB M5, M6 and M7. Semin Oncol 14: 425–434
Rivera G, Avery T, Roberts D (1975) Response of L1210 to combinations of cytosine arabinoside and VM26 or VP-16-213. Eur J Cancer 11: 639–647
Santos GW (1989) Marrow transplantation in acute non-lymphocytic leukemia. Blood 74: 901–908
Tschopp L, Von Fliedner VE, Sauter C, Maurice P, Gratwohl A, Fopp M, Cavalli F (1986) Efficacy and clinical cross-resistance of a new combination therapy (AMSA/VP-16) in previously treated patients with acute non-lymphocytic leukemia. J Clin Oncol 4: 318–324
Zittoun R, Preisler HD (1984) Reporting treatment results in non-solid tumours. In: Buyse ME, Staquet MJ, Sylvester RJ (eds) Cancer clinical trials: methods and practice. Oxford University Press, Oxford, pp 139–156
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Liang, R., Chiu, E., Chan, T.K. et al. Induction chemotherapy for newly diagnosed acute myeloid leukaemia using a regime containing cytosine arabinoside, daunorubicin and etoposide. Cancer Chemother Pharmacol 26, 380–382 (1990). https://doi.org/10.1007/BF02897299
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02897299